Professor of Hematology and Oncology, Mayo Medical School
Hematology
Dr. Morie A. Gertz, MD
|
|
Give Review
Morie A. Gertz, MD practices Hematology. He went to medical school at Loyola University Chicago Stritch School of Medicine. He has 20 awards "Jan Waldenstrom Medal for Medical and Scientific Achievements in Waldenstrom's Macroglobulinemia in Parliament", "America's Top Doctors", "America's Top Doctors for Cancer", "Bernard L. Schwartz Lecture", "Master American College Physicians", "Roland Seidler Jr. Professor of Medicine", "Excellence in Leadership Award", "Robert A. Kyle Award", "President of Staff", "IWMF Physician Service Award for Patient Education", "B. J. Kennedy Lectureship Award", "Physician Service Award for Patient Education", "President-Elect Officers and Councilors", "Distinguished Clinician Award", "Flick Family Fund Award Internal Medicine", "Physician's Recognition Award in Continuing Medical Education", "Oliver G. Marcy Scholarship for Academic Achievement", "Resident of the Year Internal Medicine", "Alpha Omega Alpha Honors Medical Society" and "Phi Beta Kappa Award". Morie A. Gertz, MD has written publications. He has 99 publications published with PubMed. The lastest paper is: 'The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.' Morie Gertz accepts Medicare payments and is registered with Medicare.gov.
Publications
- The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple Myeloma.
- First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.
- Outcomes of primary refractory multiple Myeloma and the impact of novel therapies.
- Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.
- Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple Myeloma.
- Utility of immunophenotyping of plasma cells in multiple Myeloma.
- Soluble suppression of tumorigenicity 2 (sST2), but not Galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and Tropo...
- Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.
- Clinical Course and Prognosis of Non-Secretory Multiple Myeloma.
- Multiple Myeloma after kidney transplantation.
- Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
- Quantification of clonal circulating plasma cells in relapsed multiple Myeloma.
- Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias.
- The role of bendamustine in the management of plasma cell Myeloma.
- Cost-effectiveness Analysis of early vs. late autologous stem cell transplantation in multiple myeloma.
- Risk adapted therapy for multiple Myeloma: back to basics.
- Pathophysiology and treatment of cardiac amyloidosis.
- Frequencies and Geographic Distributions of Genetic Mutations in Transthyretin- and Non-Transthyretin-Related Familial Amyloidosis.
- Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related Disorders: consensus from the Seventh International Workshop on WM.
- Long-term outcome of patients with multiple Myeloma-related advanced renal failure following auto-SCT.
- Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics.
- How we manage autologous stem cell transplantation for patients with multiple Myeloma.
- Trends in survival of patients with primary plasma cell Leukemia: a population based analysis.
- Left Ventricular Amyloid Deposition in Patients With Heart Failure and Preserved Ejection Fraction.
- Quantification of clonal circulating plasma cells in newly diagnosed multiple Myeloma: implications for redefining high-risk Myeloma.
- Yield of Noncardiac Biopsy for the Diagnosis of Transthyretin Cardiac Amyloidosis.
- High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.
- Long-term Disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.
- Domino Liver transplantation as a cause of acquired familial amyloid polyneuropathy.
- Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.
- Potential new risks of lenalidomide.
- Bortezomib-based combination regimens in Myeloma: more is not necessarily better.
- Recent advances in the diagnosis and management of cardiac amyloidosis.
- Genetic variants in DNA repair pathways are not associated with Disease progression among multiple myeloma patients.
- Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple Myeloma following lenalidomide-based initial therapy.
- Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification.
- Shining a warm light on Cryoglobulinemia.
- Long term response to lenalidomide in patients with newly diagnosed multiple Myeloma.
- Continued improvement in survival in multiple Myeloma: changes in early mortality and outcomes in older patients.
- Smoldering multiple Myeloma requiring treatment: time for a new definition?
- Low Levels of Interleukin-1 Receptor Antagonist (IL-1RA) Predict Engraftment Syndrome after Autologous Stem Cell Transplantation in POEMS Syndrome and Other Plasma Cel...
- Waldenström Macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.
- Incidence of Supraventricular Arrhythmias during Autologous Peripheral Blood Stem Cell Transplantation.
- What is Waldenström Macroglobulinemia?
- Implications of continued response after autologous stem cell transplantation for multiple Myeloma.
- A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?
- Left ventricular device implantation for advanced cardiac amyloidosis.
- Outcomes of patients with POEMS Syndrome treated initially with radiation.
- Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment.
- Chemoprevention for smoldering multiple Myeloma: not ready for prime time.
- Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple Myeloma.
- Waldenström macroglobulinaemia: the key questions.
- Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.
- Salvage autologous stem cell transplant is an effective regimen for relapsed multiple Myeloma.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
- Second auto-SCT for treatment of relapsed multiple Myeloma.
- Systemic amyloidosis associated with chronic lymphocytic Leukemia/small lymphocytic lymphoma.
- Cost-effectiveness Analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
- The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis.
- Pomalidomide and Myeloma meningitis.
- A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple Myeloma.
- Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases.
- Waldenström Macroglobulinemia: my way.
- Trends and outcomes of modern staging of solitary plasmacytoma of bone.
- What do I need to know about immunoglobulin light chain (AL) amyloidosis?
- Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
- Clinicopathologic correlations in multiple Myeloma: a case series of 190 patients with kidney biopsies.
- Waldenström Macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.
- Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials.
- Trisomies in multiple Myeloma: impact on survival in patients with high-risk cytogenetics.
- The role of PTEN and FAK in aggressive multiple Myeloma.
- High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.
- A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multi...
- Immunoglobulin D amyloidosis: a distinct entity.
- Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.
- Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis.
- Managing Light Chain Deposition Disease.
- A Reappraisal of Immunoglobulin Variable Gene Primers and Its Impact on Assessing Clonal Relationships Between PB B Cells and BM Plasma Cells in AL Amyloidosis.
- Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple Myeloma.
- The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS Syndrome.
- Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple Myeloma.
- Reducing Neurotoxicity in the Management of Multiple Myeloma.
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory Disease.
- Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple Myeloma.
- Stem cell transplant: an effective salvage therapy for multiple Myeloma.
- Early reduction of serum-free light chains associates with renal recovery in Myeloma kidney.
- Treatment of immunoglobulin light chain (primary or AL) amyloidosis.
- Establishment and characterization of a novel Waldenstrom Macroglobulinemia cell line, MWCL-1.
- Amyloidosis: pathogenesis and new therapeutic options.
- Waldenström Macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple Myeloma: Results from a phase 2 trial.
- Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following periphera...
- Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis.
- Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management.
- IgM Amyloidosis: Clinical Features in Therapeutic Outcomes.
- Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.
- Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.
- Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with Immune mo...
Schools
Loyola University Of ChicagoStritch School Of Medicine
St LukeS Hospital
Mayo Grad School Med
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Jan Waldenstrom Medal for Medical and Scientific Achievements in Waldenstrom's Macroglobulinemia in Parliament
- America's Top Doctors
- America's Top Doctors for Cancer
- Bernard L. Schwartz Lecture
- Master American College Physicians
- Roland Seidler Jr. Professor of Medicine
- Excellence in Leadership Award
- Robert A. Kyle Award
- President of Staff
- IWMF Physician Service Award for Patient Education
- B. J. Kennedy Lectureship Award
- Physician Service Award for Patient Education
- President-Elect Officers and Councilors
- Distinguished Clinician Award
- Flick Family Fund Award Internal Medicine
- Physician's Recognition Award in Continuing Medical Education
- Oliver G. Marcy Scholarship for Academic Achievement
- Resident of the Year Internal Medicine
- Alpha Omega Alpha Honors Medical Society
- Phi Beta Kappa Award
Education
-
Mayo School of Graduate Medical Education -
Rush University Medical Center -
St Joseph Hospital -
Loyola University Chicago Stritch School of Medicine -
Northwestern University
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1265402366 | |
| NPPES Provider LastName | GERTZ | |
| NPPES Provider FirstName | MORIE | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 266.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 4.14 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1265402366 |
| Last Name Of The Provider | GERTZ |
| First Name Of The Provider | MORIE |
| View All |
Similar Doctors
|
|
Dr. S Vincent Rajkumar, MD |
|
|
Dr. William J. Hogan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip R. Greipp, MD |
|
|
Dr. Lisa M. Baumann Kreuziger, MD |
|
|
Dr. Jennifer L. Herrick, MD |
|
|
Dr. Karen L. Grogg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yi Lin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arif H. Kamal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William L. Nichols, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott H. Kaufmann, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Sameer A. Parikh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carrie A. Thompson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Angela Dispenzieri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Neil E. Kay, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wei Ding, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Heidi A. McKean, MD |
|
|
Dr. Paul L. Swiecicki, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Min Shi, MD
This Doctor is OpenDoctor Recommended.
|